- Details
- Phillip Koo hosts a discussion on patient selection for radioligand therapy (RLT) in prostate cancer, featuring Amir Iravani and Evan Yu. The conversation delves into complex clinical decisions involving advanced prostate cancer management. Dr. Iravani presents a patient case to illustrate challenges faced in treatment progression, highlighting the patient’s journey through various therapies inclu...
|
- Details
- Dan George discusses the collaborative effort in managing PLUVICTO® therapy for prostate cancer with team members Kristen Davis, a Physician Assistant, and Sarah Wood, a Nurse Practitioner. Kristen describes the meticulous process of vetting patients for PLUVICTO® therapy, which includes reviewing patient information, scans, and coordinating with various departments for approval. Sarah outlines he...
|
- Details
- In a conversation with Phillip Koo, David Ulmert discusses the limitations and future directions of theranostics in prostate cancer, focusing on Lutetium-177 PSMA. Dr. Ulmert identifies the off-target effects and variable expression of PSMA as key challenges. He suggests broadening the theranostic approach beyond radioligands to include options like ADCs, CAR-T, or bispecifics. Highlighting PSMA's...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Oliver Sartor discusses radium-223's pioneering role as the first FDA-approved alpha emitter in medicine, sparking interest in radioligand therapies, and discusses its limitations, including the inability to target soft tissue. Dr. Sartor suggests that improved patient selection through PSMA PET imaging and ongoing trials exploring treatment combinations coul...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Matthias Eiber presents an overview of alpha treatment in prostate cancer, emphasizing its effectiveness in inducing DNA double-strand breaks and achieving significant therapeutic outcomes, as demonstrated through a case study of actinium PSMA, while also highlighting the challenges of managing adverse effects like xerostomia. He advocates for further researc...
|
- Details
- Daniel George hosts Michael Morris to discuss pivotal studies influencing the use of Pluvicto (lutetium PSMA-617) in treating prostate cancer. The conversation begins with the VISION study, which led to Pluvicto's approval by demonstrating significant improvements in radiographic progression-free survival (rPFS) and overall survival (OS) for patients with PSMA-positive disease. Dr. Morris outlines...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Linda Gardner and Amanda Morley detail the critical steps and challenges in setting up a Radioligand Therapy (RLT) program, covering aspects from licensing and space planning to staff training and patient care logistics. They highlight the importance of adaptability, thorough planning, and the efficient use of resources, demonstrating how UCLA and UCSF naviga...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Rahul Aggarwal presents promising preliminary data on combining radioligand therapy with immunotherapy for metastatic castration-resistant prostate cancer, suggesting this approach can transform "cold" tumors into "hot" ones, enhancing their susceptibility to immunotherapy. Highlighting the need for further research to refine dosing and address tumor heteroge...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Johannes Czernin explores the challenges of resistance in PSMA-targeted theranostics, advocating for personalized treatments based on dosimetry and strategic combination therapies to enhance efficacy and patient survival. Dr. Czernin calls for a shift in treatment approaches, emphasizing the need for optimized radiation delivery and innovative clinical trials...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Robert Flavell highlights the potential of antibody-based radiopharmaceuticals in prostate cancer treatment, addressing their high specificity and the challenges posed by their long half-lives and infusion reactions. Dr. Flavell delves into emerging research on alternative targets like DLL3 and CD46 for treating neuroendocrine and PSMA-negative prostate cance...
|
